AUGMENTING IMMUNE RESPONSES TO WEAK IMMUNOGENETICS
AUGMENTING IMMUNE RESPONSES TO WEAK IMMUNOGENETICS
批准号:
3546823
负责人:
George K Lewis
金额:
$11.04万
依托单位国家:
美国
项目类别:
财政年份:
1987
资助国家:
美国
项目状态:
已结题
起止时间:
1987-09-30 至 1990-08-31
关键词:
AIDS Freund's adjuvant antibody neutralization test antiviral antibody arsenic azobenzene enzyme linked immunosorbent assay helper T lymphocyte high performance liquid chromatography human immunodeficiency virus 1 immunization immunoconjugates immunological substance immunomodulators peptide chemical synthesis poliovirus synthetic antigens synthetic peptide synthetic vaccines tyrosine vaccinia virus viral vaccines virus antigen virus envelope
中文摘要
最近的疫苗开发革命更新了
需要简单和通用的方法来增加抗体
对弱免疫原的反应。 因此,本
研究的目的是开发这样一种方法来优化
抗体对抗原肽的反应。 的长期目标
这项研究旨在实现一种完全合成的
包含佐剂部分、载体
仅刺激T细胞的决定簇,和抗原肽
将针对其制备抗体。 本系统开发
将规避传统的
抗原肽结合的肽疫苗法
到蛋白质载体。 研究将分两个阶段进行。
第一阶段将集中在抗原肽载体
共轭 一个小的(M. W.)= 409)合成载体决定簇,L-
酪氨酸-对-偶氮苯胂酸盐(ABA-Try)将在
三种抗肽应答系统(一种脊髓灰质炎病毒VPI肽,
和两种HIV env肽)。 将特别强调
阐明抗原结构变量,因为它们影响
免疫原性 特别是,
相对于载体决定簇ABA-Tyr的抗原肽
将受到调查。 第二阶段将以第一阶段为基础,
研究合成佐剂部分与
每一个最佳共轭物。 本阶段的重点将是
取决于该部分的性质及其间距和取向
相对于抗原肽和载体决定簇。
因为第二阶段完全取决于
在第一阶段,最初只为第一阶段申请资金,
这一阶段可以在三年内完成。
英文摘要
The recent revolution in vaccine development has renewed the
need for simple and general methods to increase antibody
responses to weak immunogens. Accordingly, the present
research is aimed at development of such a method to optimize
antibody responses to antigenic peptides. The long term goal of
the proposed research is to achieve a completely synthetic
immunogen comprised of an adjuvant moiety, a carrier
determinant that only stimulates T cells, and an antigenic peptide
against which antibody will be made. Development of this system
will circumvent several of the problems inherent in the traditional
peptide-vaccine method where the antigenic peptide is conjugated
to a protein carrier. The research will proceed in two stages.
The first stage will focus on the antigenic peptide-carrier
conjugate. A small (m.w. = 409) synthetic carrier determinant, L-
Tyrosine-P-azobenzenearsonate (ABA-Try) will be evaluated in
three anti-peptide response system (one poliovirus VPI peptide,
and two HIV env peptides). Special emphasis will be placed on
elucidation of antigen-structural variables as they affect
immunogenicity. In particular the spacing and orientation of the
antigentic peptide relative to the carrier determinant ABA-Tyr
will be investigated. The second stage will build upon the first by
investigating the attachment of a synthetic adjuvant moiety to
each of the optimal conjugates. Emphasis in this stage will be
placed on the nature of the moiety and its spacing and orientation
relative to the antigenic peptide and carrier determinant.
Because the second phase is entirely dependent upon success in
the first phase, funding is initially requested only for the first
phase which can be completed in 3 years.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 2- Mechanism of How Vaccine-Elicited CD4+ T Cells Attenuate Antibody Mediated Protection
-
批准号:9141193
-
项目类别:
-
资助金额:$98.45万
-
财政年份:2016
-
负责人:George K Lewis
-
依托单位:
Broadly Neutralizing Monoclonal Antibodies Against HIV-1
-
批准号:8389642
-
项目类别:
-
资助金额:$51.43万
-
财政年份:2009
-
负责人:George K Lewis
-
依托单位:
Broadly Neutralizing Monoclonal Antibodies Against HIV-1
-
批准号:8006391
-
项目类别:
-
资助金额:$55.83万
-
财政年份:2009
-
负责人:George K Lewis
-
依托单位:
Broadly Neutralizing Monoclonal Antibodies Against HIV-1
-
批准号:8586246
-
项目类别:
-
资助金额:$54.71万
-
财政年份:2009
-
负责人:George K Lewis
-
依托单位:
Broad Neutralizing Monoclonal Antibodies From HIV Controllers
-
批准号:7929513
-
项目类别:
-
资助金额:$42.54万
-
财政年份:2009
-
负责人:George K Lewis
-
依托单位:
Broadly Neutralizing Monoclonal Antibodies Against HIV-1
-
批准号:8197904
-
项目类别:
-
资助金额:$54.71万
-
财政年份:2009
-
负责人:George K Lewis
-
依托单位:
Broad Neutralizing Monoclonal Antibodies From HIV Controllers
-
批准号:7761628
-
项目类别:
-
资助金额:$42.54万
-
财政年份:2009
-
负责人:George K Lewis
-
依托单位:
Broadly Neutralizing Monoclonal Antibodies Against HIV-1
-
批准号:7841375
-
项目类别:
-
资助金额:$56.1万
-
财政年份:2009
-
负责人:George K Lewis
-
依托单位:
VACCINE SAFETY AND IMMUNOGENICITY
-
批准号:6658274
-
项目类别:
-
资助金额:$27.48万
-
财政年份:2002
-
负责人:George K Lewis
-
依托单位:
VACCINE SAFETY AND IMMUNOGENICITY
-
批准号:6502361
-
项目类别:
-
资助金额:$27.48万
-
财政年份:2001
-
负责人:George K Lewis
-
依托单位:
NOVEL HIV VACCINES
-
批准号:6762448
-
项目类别:
-
资助金额:$95.65万
-
财政年份:2000
-
负责人:George K Lewis
-
依托单位:
NOVEL HIV VACCINES
-
批准号:6534251
-
项目类别:
-
资助金额:$122.08万
-
财政年份:2000
-
负责人:George K Lewis
-
依托单位:
VACCINE SAFETY AND IMMUNOGENICITY
-
批准号:6349684
-
项目类别:
-
资助金额:$27.48万
-
财政年份:2000
-
负责人:George K Lewis
-
依托单位:
NOVEL HIV VACCINES
-
批准号:6657984
-
项目类别:
-
资助金额:$93.43万
-
财政年份:2000
-
负责人:George K Lewis
-
依托单位:
NOVEL HIV VACCINES
-
批准号:7126566
-
项目类别:
-
资助金额:$34.3万
-
财政年份:2000
-
负责人:George K Lewis
-
依托单位:
NOVEL HIV VACCINES
-
批准号:6374498
-
项目类别:
-
资助金额:$141.93万
-
财政年份:2000
-
负责人:George K Lewis
-
依托单位:
NOVEL HIV VACCINES
-
批准号:6136257
-
项目类别:
-
资助金额:$82.43万
-
财政年份:2000
-
负责人:George K Lewis
-
依托单位:
INTEGRATED AIDS VACCINE DEVELOPMENT PROGRAM
-
批准号:2627927
-
项目类别:
-
资助金额:$56.67万
-
财政年份:1998
-
负责人:George K Lewis
-
依托单位:
MECHANISMS OF IMMUNOSENESCENCE
-
批准号:2606315
-
项目类别:
-
资助金额:$7.48万
-
财政年份:1996
-
负责人:George K Lewis
-
依托单位:
SOMATIC GENETICS OF T CELL IMMUNITY
-
批准号:2055770
-
项目类别:
-
资助金额:$21.42万
-
财政年份:1996
-
负责人:George K Lewis
-
依托单位:
海外基金